PDF(Pubmed)
Abstract：
The two inactivated SARS-CoV-2 vaccines, CoronaVac and BBIBP-CorV, have been widely used to control the COVID-19 pandemic. The influence of multiple factors on inactivated vaccine effectiveness (VE) during long-term use and against variants is not well understood.
We selected published or preprinted articles from PubMed, Embase, Scopus, Web of Science, medRxiv, BioRxiv, and the WHO COVID-19 database by 31 August 2022. We included observational studies that assessed the VE of completed primary series or homologous booster against SARS-CoV-2 infection or severe COVID-19. We used DerSimonian and Laird random-effects models to calculate pooled estimates and conducted multiple meta-regression with an information theoretic approach based on Akaike\'s Information Criterion to select the model and identify the factors associated with VE.
Fifty-one eligible studies with 151 estimates were included. For prevention of infection, VE associated with study region, variants, and time since vaccination; VE was significantly decreased against Omicron compared to Alpha (P = 0.021), primary series VE was 52.8% (95% CI, 43.3 to 60.7%) against Delta and 16.4% (95% CI, 9.5 to 22.8%) against Omicron, and booster dose VE was 65.2% (95% CI, 48.3 to 76.6%) against Delta and 20.3% (95% CI, 10.5 to 28.0%) against Omicron; primary VE decreased significantly after 180 days (P = 0.022). For the prevention of severe COVID-19, VE associated with vaccine doses, age, study region, variants, study design, and study population type; booster VE increased significantly (P = 0.001) compared to primary; though VE decreased significantly against Gamma (P = 0.034), Delta (P = 0.001), and Omicron (P = 0.001) compared to Alpha, primary and booster VEs were all above 60% against each variant.
Inactivated vaccine protection against SARS-CoV-2 infection was moderate, decreased significantly after 6 months following primary vaccination, and was restored by booster vaccination. VE against severe COVID-19 was greatest after boosting and did not decrease over time, sustained for over 6 months after the primary series, and more evidence is needed to assess the duration of booster VE. VE varied by variants, most notably against Omicron. It is necessary to ensure booster vaccination of everyone eligible for SARS-CoV-2 vaccines and continue monitoring virus evolution and VE.
PROSPERO, CRD42022353272.
We selected published or preprinted articles from PubMed, Embase, Scopus, Web of Science, medRxiv, BioRxiv, and the WHO COVID-19 database by 31 August 2022. We included observational studies that assessed the VE of completed primary series or homologous booster against SARS-CoV-2 infection or severe COVID-19. We used DerSimonian and Laird random-effects models to calculate pooled estimates and conducted multiple meta-regression with an information theoretic approach based on Akaike\'s Information Criterion to select the model and identify the factors associated with VE.
Fifty-one eligible studies with 151 estimates were included. For prevention of infection, VE associated with study region, variants, and time since vaccination; VE was significantly decreased against Omicron compared to Alpha (P = 0.021), primary series VE was 52.8% (95% CI, 43.3 to 60.7%) against Delta and 16.4% (95% CI, 9.5 to 22.8%) against Omicron, and booster dose VE was 65.2% (95% CI, 48.3 to 76.6%) against Delta and 20.3% (95% CI, 10.5 to 28.0%) against Omicron; primary VE decreased significantly after 180 days (P = 0.022). For the prevention of severe COVID-19, VE associated with vaccine doses, age, study region, variants, study design, and study population type; booster VE increased significantly (P = 0.001) compared to primary; though VE decreased significantly against Gamma (P = 0.034), Delta (P = 0.001), and Omicron (P = 0.001) compared to Alpha, primary and booster VEs were all above 60% against each variant.
Inactivated vaccine protection against SARS-CoV-2 infection was moderate, decreased significantly after 6 months following primary vaccination, and was restored by booster vaccination. VE against severe COVID-19 was greatest after boosting and did not decrease over time, sustained for over 6 months after the primary series, and more evidence is needed to assess the duration of booster VE. VE varied by variants, most notably against Omicron. It is necessary to ensure booster vaccination of everyone eligible for SARS-CoV-2 vaccines and continue monitoring virus evolution and VE.
PROSPERO, CRD42022353272.
摘要：
背景：两种灭活的SARS-CoV-2疫苗，CoronaVac和BBIBP-CorV，已被广泛用于控制COVID-19大流行。多种因素对长期使用和针对变体的灭活疫苗有效性（VE）的影响尚不清楚。
方法：我们选择了PubMed的已发表或预印的文章，Embase,Scopus,WebofScience,medRxiv,BioRxiv,并在2022年8月31日之前建立WHOCOVID-19数据库。我们纳入了观察性研究，评估了完成的初级系列或同源加强剂对SARS-CoV-2感染或严重COVID-19的VE。我们使用DerSimonian和Laird随机效应模型计算合并估计值，并使用基于Akaike的信息标准的信息理论方法进行多元元回归，以选择模型并确定与VE相关的因素。
结果：纳入51项符合条件的研究，151项估计。为了预防感染，与研究区域相关的VE，变体,和接种后的时间；与α相比，Omicron的VE显着降低（P=0.021），主要系列VE对Delta为52.8%(95%CI，43.3至60.7%)，对Omicron为16.4%(95%CI，9.5至22.8%)，加强剂量VE对Delta为65.2%(95%CI,48.3~76.6%),对Omicron为20.3%(95%CI,10.5~28.0%);180天后原发性VE显著下降(P=0.022)。为了预防与疫苗剂量相关的严重COVID-19、VE，年龄,研究区域,变体,研究设计，和研究人群类型；与原发性相比，助推器VE显着增加（P=0.001）；尽管VE对Gamma显着降低（P=0.034），Delta（P=0.001），和Omicron(P=0.001)与Alpha相比，针对每个变异体的主要和加强VE均超过60%.
结论：灭活疫苗对SARS-CoV-2感染的保护作用中等，初次疫苗接种后6个月后显著下降，并通过加强疫苗接种恢复。对严重COVID-19的VE在增强后最大，并没有随着时间的推移而下降，在主要系列比赛后持续了6个月以上，需要更多的证据来评估助推器VE的持续时间。VE因变体而异，最值得注意的是对抗Omicron。有必要确保每个有资格获得SARS-CoV-2疫苗的人都进行加强疫苗接种，并继续监测病毒进化和VE。
背景：PROSPERO，CRD42022353272。
方法：我们选择了PubMed的已发表或预印的文章，Embase,Scopus,WebofScience,medRxiv,BioRxiv,并在2022年8月31日之前建立WHOCOVID-19数据库。我们纳入了观察性研究，评估了完成的初级系列或同源加强剂对SARS-CoV-2感染或严重COVID-19的VE。我们使用DerSimonian和Laird随机效应模型计算合并估计值，并使用基于Akaike的信息标准的信息理论方法进行多元元回归，以选择模型并确定与VE相关的因素。
结果：纳入51项符合条件的研究，151项估计。为了预防感染，与研究区域相关的VE，变体,和接种后的时间；与α相比，Omicron的VE显着降低（P=0.021），主要系列VE对Delta为52.8%(95%CI，43.3至60.7%)，对Omicron为16.4%(95%CI，9.5至22.8%)，加强剂量VE对Delta为65.2%(95%CI,48.3~76.6%),对Omicron为20.3%(95%CI,10.5~28.0%);180天后原发性VE显著下降(P=0.022)。为了预防与疫苗剂量相关的严重COVID-19、VE，年龄,研究区域,变体,研究设计，和研究人群类型；与原发性相比，助推器VE显着增加（P=0.001）；尽管VE对Gamma显着降低（P=0.034），Delta（P=0.001），和Omicron(P=0.001)与Alpha相比，针对每个变异体的主要和加强VE均超过60%.
结论：灭活疫苗对SARS-CoV-2感染的保护作用中等，初次疫苗接种后6个月后显著下降，并通过加强疫苗接种恢复。对严重COVID-19的VE在增强后最大，并没有随着时间的推移而下降，在主要系列比赛后持续了6个月以上，需要更多的证据来评估助推器VE的持续时间。VE因变体而异，最值得注意的是对抗Omicron。有必要确保每个有资格获得SARS-CoV-2疫苗的人都进行加强疫苗接种，并继续监测病毒进化和VE。
背景：PROSPERO，CRD42022353272。
